ABVX vs. BLTE, TVTX, IRON, WVE, IOVA, EVO, PRAX, AMPH, GLPG, and AAPG
Should you be buying ABIVAX Société Anonyme stock or one of its competitors? The main competitors of ABIVAX Société Anonyme include Belite Bio (BLTE), Travere Therapeutics (TVTX), Disc Medicine (IRON), Wave Life Sciences (WVE), Iovance Biotherapeutics (IOVA), Evotec (EVO), Praxis Precision Medicines (PRAX), Amphastar Pharmaceuticals (AMPH), Galapagos (GLPG), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.
ABIVAX Société Anonyme vs.
ABIVAX Société Anonyme (NASDAQ:ABVX) and Belite Bio (NASDAQ:BLTE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
ABIVAX Société Anonyme's return on equity of 0.00% beat Belite Bio's return on equity.
ABIVAX Société Anonyme has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.59, suggesting that its share price is 259% less volatile than the S&P 500.
In the previous week, ABIVAX Société Anonyme had 2 more articles in the media than Belite Bio. MarketBeat recorded 3 mentions for ABIVAX Société Anonyme and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.50 beat ABIVAX Société Anonyme's score of 0.45 indicating that Belite Bio is being referred to more favorably in the news media.
Belite Bio received 22 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. Likewise, 96.88% of users gave Belite Bio an outperform vote while only 81.82% of users gave ABIVAX Société Anonyme an outperform vote.
ABIVAX Société Anonyme presently has a consensus price target of $38.67, suggesting a potential upside of 378.55%. Belite Bio has a consensus price target of $96.33, suggesting a potential upside of 69.01%. Given ABIVAX Société Anonyme's higher possible upside, research analysts clearly believe ABIVAX Société Anonyme is more favorable than Belite Bio.
47.9% of ABIVAX Société Anonyme shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
ABIVAX Société Anonyme beats Belite Bio on 8 of the 13 factors compared between the two stocks.
Get ABIVAX Société Anonyme News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ABIVAX Société Anonyme Competitors List
Related Companies and Tools
This page (NASDAQ:ABVX) was last updated on 2/22/2025 by MarketBeat.com Staff
